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 3 LIST OF ABBREVIATIONS 
 
 
 
AKT   protein kinase B (PKB), also known as Akt, 
ANOVA  analysis of variance 
AP-PA  anterior-posterior-posterio-anterior 
AWTd  anterior wall thickness diastolic 
AWTs   anterior wall thickness systolic 
BCA   bicinchoninic acid assay 
BrdU   5-bromo-2'-deoxyuridine  
BSA   bovine serum albumin 
calcein-AM calcein acetoxymethyl ester 
cAMP  cyclic adenosine monophosphate 
CT   computed tomography 
DNA   deoxyribonucleic acid 
DCFH-DA  dichloro-dihydro-fluorescein diacetate assay 
D-PBS  Dulbecco's phosphate-buffered Saline 
E/e’   ratio of the early flow velocity (E) and the septal mitral annulus    
   velocity e' 
ECG   electrocardiogram 
ELISA  enzyme-linked immunosorbent assay 
ERK1/2  extracellular signal-regulated kinase ½ 
FBS   fetal bovine serum 
FS   fractional shortening 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
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GDF-15  growth differentiation factor-15 
GH   growth hormone 
GHRH  growth hormone-releasing hormone 
hGHRH  human growth hormone-releasing hormone 
HR   heart rate  
HRP   horseradish peroxidase 
HSL   hue, saturation, luminance  
IMRT  intensity-modulated radiotherapy 
IVCT  isovolumic contraction time 
JAK2/STAT3 Janus kinase2/ Signal Transducer and Activator of Transcription3 
LSD   least significant difference  
LVEDD  left ventricular end diastolic diameter 
LVESD  left ventricular end dystolic diameter 
LVOT PGmax left ventricular outflow tract maximal pressure gradient 
LVOT vmax left ventricular outflow tract maximal flow velocity 
NRVM  newborn rat ventricular myocytes 
pGHRHR  pituitary receptor of growth hormone-releasing hormone  
PI3K   phosphatidil-inositol-3-kinase 
PMMA  poly(methyl metacrylate) 
RGB   red, green, blue  
RIHD  radiation-induced heart disease 
RIPA  radioimmunoprecipitation assay lysis buffer 
ROS   reactive oxygen species 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SV   splice variants 
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SWTd  septal wall thickness diastolic 
SWTs  septal wall thickness systolic 
TGF-β  transforming growth factor-beta 
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4 INTRODUCTION 
 
4.1 Radiation-induced heart damage and clinical importance 
 Radiotherapy is an essential part of anti-cancer therapy. Radiation-induced heart diseases 
(RIHD) including ischemic heart disease, congestive heart failure, electrical conduct defects and 
valve abnormalities are typically late consequences of radiotherapy, occurring many years or 
decades after treatment [1, 2]. Substantial number of irradiated patients may suffer from late side-
effects, these develop after chest irradiation in childhood cancers, lung, esophageal or breast 
cancer or Hodgkin’s lymphoma [3, 4]. These often-unattributed complications cause deterioration 
in quality of life of long-surviving patients, extra health care costs, and lead occasionally to fatal 
outcomes. Previous studies have described that the heart damage caused by irradiation is dose-
related and only develops many years after the radiation treatment [1, 5, 6, 7]. Although with 
development of modern radiotherapy techniques significantly reduce the dose to the heart, in 
many cases, the whole heart or a part of it still receives a dose adequate to cause RIHD. 
4.2 The pathomechanisms of radiation-induced heart disease (RIHD)  
 Presentation and monitoring of the radiation sensitivity of the heart occurred first in the 
1970s, but currently the heart is regarded as one of the most critical dose-limiting organs in 
radiation therapy. The development of RIHD is dose-dependent, and is more possible if radiation 
exposure occurs at a younger age [8, 9]. Ionizing radiation may be harmful to virtually all of the 
cardiac structures, but micro- and macrovascular damage formation seem to be the most 
important responsible pathomechanism. The most important epidemiological data on the 
occurrence of radiogenic cardiovascular disease originate from breast cancer studies. Darby et al., 
analyzing the SEER database of more than 300,000 patients, found that among those who 
received adjuvant radiotherapy, the patients with left sided tumors had a significantly increased 
risk of cardiac death due to cardiovascular diseases or myocardial infarction, appearing 10 years 
after the irradiation, and increasing further thereafter [6, 10]. It seems possible, that the 
radiogenic damage of the macrovasculature of the heart occurs after the exposure of these 
structures to relatively high doses. Animal experiments revealed inflammatory and oxidative 
damage leading to the formation of typical atherosclerotic plaques [4, 11]. Radiation-induced 
diffuse myocardium changes include microvasculature abnormalities, degenerative 
10 
 
cardiomyocyte and interstitial fibrotic changes. Such abnormalities may develop after even low 
dose radiation exposure, and can result in the deterioration of the heart’s pump function or in 
cardiac conduction abnormalities [5]. Cilliers et al., investigated radiation-induced time-
dependent changes of the myocardium in Wistar rats [12]. Interestingly, the radiation induced 
structural changes of the endothelial cells and myocytes developed early after the irradiation, and 
were accompanied by a transitory depression of the mechanical function of the heart; 100-180 
days after the irradiation, only interstitial inflammation and fibrosis were present. Radiation 
induces inflammatory responses, and activates senescence pathways; there is a need to test new 
agents that could prevent these cellular responses. 
 The study of the pathomechanisms of RIHD, the identification of its early predictors, and 
its prevention by the administration of protective agents are relevant research perspectives 
studied under both experimental and clinical research conditions [4, 13]. Although different 
experimental approaches have been tested to model the clinical scenario of RIHD, the results 
obtained so far are rather contradictory, and only few of the in vivo models applied selective heart 
irradiation [5]. Early experiments focused on radiation-induced pericarditis in rabbits and dogs 
achieved with relatively high dose and short observational time, a steep dose response was found 
between 15-20 Gy [5]. Most experience was collected in murine models, despite that in these 
species the different structures of the heart show less radiosensitivity than in larger animals. The 
characteristics of RIHD including dose tolerance, pathophysiological consequences, latency 
times, and pathomechanisms vary according to the breed. Using Wistar rats, Lauk et al. 
demonstrated ventilatory failure accompanied with pleural effusion that developed earlier and in 
a more severe form at a higher (i.e. 20-40 Gy) than a lower (<20 Gy) heart dose [14]. High-dose 
irradiation caused life-threatening radiation pericarditis, and the animals had to be sacrificed; no 
long-term follow-up results could be collected. However, ECG changes, arrhythmias and 
histological changes of the myocardium such as the degeneration and loss of cardiomyocytes, the 
development of interstitial fibrosis and the reduction of capillaries in the myocardium did not 
show clear dose-dependence [15]. Yeung et al., in Sprague-Dawley rats, >6 months after the 
delivery of a single dose of 30-50 Gy to the heart, experienced dose-dependent vascular damage 
and decreased cardiac output, but no or insignificant fibrosis [15]. Sharma et al., developed an 
image-guided irradiation technique in Sprague-Dawley rats, and after the delivery of 21 Gy to the 
heart, found myocardial degeneration and fibrosis [16]. 
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4.3 Acute inflammatory markers in RIHD 
In clinical practice, the signs and symptoms of RIHD develop many years after radiation 
exposure, early predictive markers would be useful. Transforming growth factor-beta (TGF-beta) 
and growth differentiation factor-15 (GDF-15) belong to the TGF-beta/bone morphogenetic 
protein (BMP) superfamily involved in the regulation of cell proliferation, differentiation, 
apoptosis, inflammation and tumorigenesis [17, 18, 19]. TGF-beta is a key cytokine implicated in 
the development of radiation injury of various tissues [20, 21]. In cardiovascular diseases, GDF-
15 has great potential as a biomarker [17, 18, 22]. 
4.4 Growth Hormone-Releasing Hormone (GHRH) 
Growth hormone-releasing hormone (GHRH) was first identified in humans as a hypothalamic 
peptide hormone which primarily regulates the production and release of pituitary growth 
hormone (GH) (Figure 1) [23]. Lately, the expression of GHRH has also been demonstrated in a 
series of normal and cancerous tissues [24]. The pituitary receptor of GHRH (pGHRHR) belongs 
to the class type-II G protein-coupled receptors [25], the binding induces the production of cAMP 
that triggers a series of intracellular signaling cascades. The presence of its splice variants 
(mainly SV1, less importantly SV2, SV3) has been demonstrated in a series of peripheral normal 
tissues and in a variety of cancers [26, 27, 28]. Stimulation of the GHRHR results in the 
activation of the ERK1/2, AKT, JAK2/STAT3, PI3K/AKT pathways [29]. Numerous 
experimental data support the autocrine-paracrine role of the GHRH system with beneficial 
effects on tissue regeneration. GHRH has been shown to promote survival and inhibit apoptosis 
in cardiomyocytes in vitro despite serum starvation or isoproterenol treatment [30]. Kanashiro-
Takeuchi et al described that the expression and activation of pGHRHR after GHRH 
administration were demonstrated in both adult rat ventricular myocytes and in H9c2 embryonic 
rat heart cells, which expressed pGHRHR [31].  
 GHRH prevented death of adult rat cardiac myocytes induced by serum starvation or by 
isoproterenol treatment, which was antagonized by antagonistic analog of GHRH, JV-1-36. 
These protective effects were mediated by the activation of the extracellular signal-regulated 
kinase (ERK)1/2 and phosphoinositide-3 kinase (PI3K)/Akt signaling pathways. Additionally, 
isolated rat hearts subjected to ischemia-reperfusion (I/R) injury were protected by the 
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administration of GHRH before ischemia, which was abolished if co-administered with JV-1-36 
[30]. Penna at al. demonstrated similar results in the isolated rat heart model; the administration 
of GHRH at the onset of reperfusion reduced the size of the infarct, and this effect was abrogated 
if JV-1-36 was co-administered (antagonistic analog of GHRH) [32]. 
 
Figure 1. Possible mechanisms of stimulating effects of GHRH and GHRH agonists on healthy 
organs and tumors. 
  
 Kanashiro-Takeuchi demonstrated that the administration of the GHRH agonist, JI-38, 
reversed ventricular remodeling and enhanced functional recovery after myocardial infarction, 
while reducing experimental infarct size in rats [33]. These effects were absent if a GHRH 
antagonist was co-administered, or by treatment with GH only. These effects point to the role of a 
GHRHR-mediated mechanism. Following the demonstration of beneficial results of the JI class 
of agonistic analogs of GHRH in multiple fields, new classes of GHRH agonists have been 
developed with the ultimate goal of clinical use [34]. As noted some of them have been tested in 
the experimental myocardial infarct rat model, which confirmed the cardioprotective effects of 
GHRH agonists by measurement of infarct size and heart function [34, 35]. 
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5 AIMS 
 
 
 
The following aims were defined: 
 
1. The development of an in vitro model appropriate for the study of the components and some 
pathomechanisms of RIHD and also for testing potential protective agents 
 
2. The investigation of the possible role of GHRH and its receptors in irradiated cardiomyocytes 
 
3. The in vitro study of the effects of GHRH and its agonistic analogs, JI-34 and MR-356, in 
both irradiated and unirradiated cardiomyocytes 
 
4. The development of an in vivo model for the comprehensive study of RIHD after selective 
heart irradiation, with heart functional, imaging, biochemical and morphological 
endpoints  
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6 MATERIALS AND METHODS 
 
This investigation conformed to the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and was approved by the local 
ethics committee at the University of Szeged. 
 
6.1 Experimental design and protocol of the in vitro study  
 
In this series of experiments, the effects of irradiation and GHRH treatment on survival 
and various radiogenic stress-related biochemical changes of newborn rat ventricular myocyte 
(NRVM) cell cultures were assessed.  
6.1.1 Neonatal cardiac myocyte preparation, culturing and irradiation  
 
NRVM were isolated as previously described [36]. Briefly, newborn Wistar rats were 
disinfected with 70% ethanol and then killed by cervical dislocation. Hearts were excised and 
transferred to cold phosphate-buffered saline (PBS), pH 7.2. The ventricles were separated, 
minced gently by fine forceps and digested in 0.25% trypsin solution (5 ml/heart) at 37 °C for 25 
minutes. The cell suspension was then centrifuged at 2000 RPM at 4 °C for 15 minutes. Pellets 
were resuspended in growth medium (Dulbecco’s MEM supplemented with 10% fetal bovine 
serum [FBS], 0.1% glutamine, 0.1% Antibiotic/Antimycotic solution) and plated onto 6-well 
plates to eliminate fibroblasts at 37 °C for 90 minutes (pre-plating step). Cells of the supernatant 
were then re-plated onto fresh 6- and 96-well plates and flasks (5 x 10
5
, 15 x 10
4
 and 4 x 10
6
 
cells/well, respectively). NRVM were supplied with 2 ml, 150 μl and 20 ml per well growth 
medium with or without 10% FBS in 6-well, 96-well plates and flasks, respectively, and were 
incubated at 37 °C and 5% CO2. The experiments were started 24 hours after plating. First, the 
cell cultures were irradiated with a linear accelerator (Siemens Primus, Siemens Medical 
Solutions, USA), 6 MV energy photon beams with opposing field technique. To achieve a 
homogeneous dose distribution in the sample, 2 cm thick PMMA sheets were applied. (Figure 2) 
15 
 
 
Figure 2 Experimental protocol. To assess the protective effects of GHRH agonists, NRVM 
were isolated and cultured from newborn rats. The 24-hour cultures were exposed to 10 Gy dose 
of radiation, and the effect was examined at different latency times (0, 6, 12, 24, 48 h). The cells 
were cultured in either in differentiation medium or serum-free medium and the toxicity of the 
radiation was evaluated with calcein fluorescence viability assay and BrdU proliferation assay. 
Western blot analysis was performed to detect the presence of GHRH receptors, before and after 
the irradiation. 
 
6.1.2 Testing of GHRH agonist treatment 
 
First, the effects of synthetic human GHRH (hGHRH) (Bertin Pharma, Montigny le 
Bretonneux, France) was tested at concentrations of 1, 10, 50, and 100 nM in unirradiated and 
irradiated cell cultures. Next, GHRH agonists, JI-34 and MR-356, were studied both in 
unirradiated and irradiated cell cultures at concentrations of 1, 10, 50, 100 and 500 nM in cultures 
with or without 1% FBS supplementation (for JI-34). Cell viability and proliferation assays were 
performed 48 hours thereafter. (Figure 2) 
NRVM cultures maintained in FBS-supplemented medium were also studied for GHRHR 
expression and possible involved signaling pathways by Western blot analyses as follows: 1. non-
irradiated, non-treated, 2. non-irradiated, JI-34-treated, 3. irradiated, non-treated, 4. irradiated and 
JI-34-treated; in these experiments, JI-34 was applied at the most effective concentration of 10 
nM. Cells were collected 1 and 48 hours after the irradiation.  
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6.1.3 Cell viability and proliferation assays 
 
Both tests were performed following the respective experimental procedure (irradiation 
and/or treatment). For the assessment of cell viability, NRVM were incubated with 1 μM calcein 
acetoxymethyl ester (calcein-AM, Sigma, St Louis, MO) at room temperature for 30 minutes. 
Fluorescence intensity was measured with a fluorescence plate reader (Fluostar Optima, BMG 
Labtech, Ortenberg, Germany) [37]. Cell viability was compared to that of vehicle control. Each 
plate contained non-irradiated columns serving as technical controls. 
For the assessment of cell proliferation the NRVM cultures were incubated and labeled 
with 10 μl/well 5-bromo-2'-deoxyuridine (BrdU) (Cell Proliferation ELISA, BrdU (colorimetric), 
Roche, Germany) labeling solution at 37 °C, 5% CO2 for 20 hours. Then the labeling medium 
was removed, the cells fixed, and the DNA was denatured in one step with fix/denature solution. 
Then an anti-BrdU mouse monoclonal antibody was added followed by an HRP conjugated 
secondary antibody to detect the incorporated BrdU. The absorbance intensity was measured with 
a plate reader. 
6.1.4 Western blot analysis 
After the indicated time of incubation, cell cultures were washed with D-PBS and 
incubated for 5 minutes in homogenization buffer (1x RIPA supplemented with a protease and 
phosphatase inhibitor cocktail). Then cells were scraped, collected and sonicated with an 
ultrasound homogenizer for 10 seconds on ice. The homogenate was centrifuged at 11800 RPM, 
4 °C for 10 minutes (Hettich Universal 320R Centrifuge, Andreas Hettich GmbH and Co., 
Tuttlingen, Germany); the supernatant was transferred into a concentrating tube (Amicon® Ultra-
4 Centrifugal Filter Units, 10 kDa MWCO), and was centrifuged again at 6300 RPM, 4 °C for 20 
minutes. The concentrated sample was collected and stored at -80 °C. 
Protein concentration was measured with bicinchoninic acid (BCA) assay (Pierce™ BCA 
Protein Assay Kit, Thermo Fisher Scientific Inc., Waltham, MA USA) by reading the optical 
density at UV max of 560 nm, and calculating automatically by the Anthos software. Twenty μg 
samples of protein were loaded on SDS-PAGE (10%) followed by the transfer of proteins onto a 
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nitrocellulose membrane (90 V, 1 hour). Membranes were then blocked overnight at 4 °C in 1% 
bovine serum albumin (BSA). Membranes were incubated both with GHRH receptor antibody 
(1:1000, ab76263, Abcam Inc., Cambridge, MA) and GAPDH antibody (1:5000, Cell Signaling 
Technology, Danvers, MA) for 1.5 hours at room temperature in 1% BSA (Cell Signaling 
Technology, Danvers, MA) and then anti-rabbit HRP secondary antibody (1:2000; 1:10000, 
Dako, Glostrup, Denmark) for 40 minutes. Membranes were then developed with an enhanced 
chemiluminescence kit (GE HealthCare, Little Chalfont, UK), exposed to X-ray film (Kodak, 
Rochester, NY, US), and scanned [38]. 
6.1.5 Examination of appearance of apoptosis markers 
 
For the analysis of ERK and Akt, equal amounts of protein (20 µg) were mixed with 
reducing 5× Laemmli buffer, loaded and separated in 4-20% precast Tris-glycine SDS 
polyacrylamide gels (Bio-Rad Hungary Ltd., Budapest, Hungary). Proteins were transferred onto 
a polyvinylidene difluoride membrane (Bio-Rad Hungary Ltd., Budapest, Hungary) at 350 mA 
for 2 h. Transfer was visualized with Ponceau staining (Sigma, St Louis, MO). Membranes were 
blocked with 5% BSA (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) in Tris-buffered 
saline containing 0.05% Tween-20 (0.05% TBS-T; Sigma, St Louis, MO) at room temperature 
for 2 h. Membranes were probed with primary antibodies (dilution 1:1000) overnight at 4 °C 
(phospho-Akt [Ser473] - #9271; Akt - #9272; phospho-Erk1/2 [Thr202/Tyr204] - #9106; Erk1/2 
- #9107; GAPDH - #5174), and with corresponding HRP-conjugated secondary antibodies (Cell 
Signaling Technology, Danvers, MA) for 2 h at room temperature. Signals were detected with the 
chemiluminescence kit. Quantification was made by calculating intensity ratio by Image Lab 4.1 
(Image Lab™ Software, Bio-Rad Laboratories, Inc., California, USA). Antibodies detecting 
phosphorylated epitopes were removed with Pierce stripping buffer (Thermo Scientific Labor 
Kft., Budapest, Hungary) before incubation with antibodies detecting the total protein. 
6.1.6 DHE staining for oxidative stress detection 
 
The presence of superoxide was detected with a plate reader using the oxidative 
fluorescent dye dihydroethidium (DHE) (Sigma St Louis, MO; D7008). Cell membranes are 
freely permeable to DHE that fluoresces red when oxidized to ethidium in the presence of 
superoxide. The presence of general reactive oxygen species (ROS) production was detected by 
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dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay (Sigma; D6883). Cardiac myocytes 
were rinsed with PBS, and then incubated with 10 µM DHE or DCFH-DA at room temperature 
for 60 min in a dark chamber, after removing extra dye with D-PBS (pH 7.4), the fluorescence 
intensity was measured [39]. 
 
6.2 Experimental design and protocol of the in vivo study 
 
In the animal experiments, the observation of the acute, subacute and late effects of a 
single shot of relatively large radiation dose was aimed at. Physiology, heart function, 
biochemical and morphology endpoints were defined. 
The experiments were performed using male Sprague-Dawley rats weighing 
approximately 180–200 g. The animals were housed in three in individually ventilated cages 
(Sealsafe IVC system, Italy) and were maintained in a temperature-controlled room with 12 h : 
12 h light/dark cycles throughout the study. Standard rat chow supplemented with 5% fat (Innovo 
Kft., Gödöllő, Hungary) and tap water were supplied ad libitum throughout the experiment [40]. 
6.2.1 Experimental setup 
 
Two preliminary experiments focused on dose finding and optimum timing of tests for the 
prespecified endpoints. In the first experiment, 5 groups of 2 animals each were selected, and 4 
groups were irradiated with 20 Gy, 25 Gy, 30 Gy and 40 Gy, respectively, while the control 
group remained unirradiated. The observation period lasted for 14 weeks after the irradiation. In 
the second experiment, 4 groups of 5 animals each were irradiated with 50 Gy, and the 
observation time lasted for 14, 18, 22 or 26 weeks. An unirradiated group of the same size was 
observed for 26 weeks. In these preliminary experiments, feasibility was studied by means of 
weight gain, ventilatory symptoms and animal loss. Circulating cytokine tests and 
echocardiographies (at weeks 0, 3, 8, 10 and 26) were performed for orientation, and heart 
pathology was studied with special attention to fibrosis and other radiogenic abnormalities.   
In the third experiment, the animals were divided into control and irradiated groups (n=12 each) 
(Figure 3). In the irradiated group, a single dose of 50 Gy was delivered to the whole heart. Body 
weight was measured every week in both groups. At weeks 0, 3, 12 and 19, cardiac morphology 
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and function were assessed by transthoracic echocardiography and ECG (Figure 3). At weeks 0, 3 
and 8, 1 ml blood samples were carefully collected with 25G needles from the tail vein into 
heparinized Eppendorf tubes. Plasma was separated by centrifugation at 4460 RPM, 10 min, 4 
°C, and stored until measurements at -70 °C. 
Despite the initial plan to follow up the animals for 24-28 weeks, at week 19, autopsy was carried 
out because of status deterioration, and the organs were removed for different examinations. 
 
Figure 3 Experimental setup. Sprague-Dawley rats after sham or selective heart irradiation 
were examined by means of echocardiography, blood tests for circulating inflammatory cytokines 
and pathological studies focusing on the heart (A). A typical verification image of selective heart 
irradiation is shown (B). 
 
6.2.2 Selective heart irradiation 
 
Based on the CT morphology of the heart in 3 months-old Sprague-Dawley rats in the 
supine position, the irradiation was carried out with a single spherical field. According to the 
depth and transverse dose distribution, the 6 MeV energy electron beam collimated with a 2 cm 
circular applicator was selected. The measurements were carried out using a water phantom with 
a pinpoint ionization chamber (PTW, Freiburg GmbH, Germany). Dose was prescribed as a mean 
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dose to a 1 cm spherical volume 3 mm below the body surface.  
The rats were anesthetized with sodium pentobarbital (Euthasol; ip. 40 mg/kg; Produlab Pharma 
b.v., Raamsdonksveer, The Netherlands), then fixed in supine position to a flat surface couch. 
The radiation dose was delivered with a Primus linear accelerator (Siemens Healthcare GmbH, 
Erlangen, Germany) at a dose intensity of 5 Gy/min if the appropriate position of the animal was 
proved by the verification film obtained with the radiation beam. 
6.2.3 Transthoracic echocardiography 
 
Echocardiography with a Vivid 7 Dimension ultrasound system (General Electric Medical 
Systems, Budapest, Hungary) using a phased array 5.5–12 MHz transducer (10S probe) was 
carried out at weeks 0, 12 and 19. The rats were anesthetized with 2% isoflurane (Forane, 100 ml, 
AESICA, Queenborough Limited Kent, UK), the chest was shaved, and the animal was placed in 
supine position onto a heating pad. Echocardiography was performed as described previously 
[41]. Moreover, maximal flow velocity and pressure gradient through the left ventricular outflow 
tract were assessed by continuous-wave Doppler across the aortic valve from the parasternal long 
axis view. Diastolic function was assessed using pulse-wave Doppler across the mitral valve from 
the apical four-chamber view. Early (E) and atrial (A) flow velocity as well as their ratio provide 
an indication of diastolic function. The septal mitral annulus velocity e' was assessed by tissue 
Doppler imaging as an early indicator of left ventricular diastolic dysfunction. The mean values 
of three measurements were calculated and used for statistical evaluation (EchoPac Dimension 
software; General Electric Medical Systems, Budapest, Hungary). 
6.2.4 Measurement of GDF-15 and TGF-beta1 in plasma 
 
Levels of plasma GDF-15 and TGF-beta1 protein were determined in blood taken from 
the rats the day before and 3, 8, 12 and 26 weeks (preliminary experiment) after the irradiation. 
Confirmatory measurement of GDF-15 concentrations was performed on samples taken in the 
third experiment before and 3 and 6 weeks after the irradiation. Cytokine levels were determined 
using the Quantikine Rat GDF-15/TGF-beta1 ELISA kit (R&D Systems, Minneapolis, MN) 
according to the manufacturer’s instructions. Optical densities were measured with fluorescent 
plate reader at 450 nm wavelength (Synergy HT, Biotec, USA). 
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6.2.5 Tissue harvesting  
 
In the third experiment, at week 19, rats were anesthetized with sodium pentobarbital, the 
chest was opened, and the heart was excised and placed in ice-cold Krebs-Henseleit buffer. After 
rapid cannulation of the aorta, the heart was perfused for 5 min at 37 °C according to 
Langendorff with oxygenated Krebs-Henseleit buffer as previously described [41, 42] in order to 
wash out the blood. After the ex vivo perfusion, the hearts were weighed, and a cross section of 
the whole heart at the ring of the papillae was cut and fixed in 10% buffered formalin for 
histological analysis. Following the removal of the heart, pleural fluid was collected from the 
chest, its volume was measured, and all the other organs were weighed. 
6.2.6 Histology and computerized image analysis of fibrosis in the heart 
 
Transverse cut sections of the formalin-fixed subvalvular area of the ventricles were 
embedded in paraffin. Five-micrometer-thick sections were stained with both conventional 
hematoxylin-eosin and picrosirius red for the detection of collagen [43]. In the preliminary 
experiments, picrosirius red staining of the sections was semiquantitatively evaluated by 2 
independent pathologists blinded to the treatment received. Based on these results, in the third 
experiment, a computerized image analysis method was developed. Histological slides were 
scanned with a Pannoramic P250 scanner (3D-Histech, Budapest, Hungary), and digital images at 
magnification of x1.5 (whole transection area) and x20 (3 specified areas of the left ventricle: 
anterior, lateral and posterior wall, septum and lateral wall of the right ventricle) were captured. 
Care was taken to avoid medium-size vessels and their perivascular connective tissue sheet, the 
subepicardial and subendocardial areas. Digital images of the whole heart at x1.5 magnification 
fitting the screen were also captured. The saved images were analyzed with the help of an in-
house developed program which uses two simple color filters for determining the proportion of 
red in the heart. The first filter is used for detecting red portions of the picture. For each red, 
green, blue (RGB) pixel making up the image, the program calculates the color of the pixel in 
hue, saturation, luminance (HSL) color space. The second filter excludes any white (empty) or 
light grey (residual dirt on the slide) pixel from further processing using simple RGB threshold. 
In this way, the program groups each pixel into one of two sets: pixels considered red (connective 
tissue and fibrosis), and pixels considered neither red, nor white, nor grey (i.e. green, 
corresponding to cardiac muscle). Dividing the number of elements in the first set by the number 
22 
 
of elements in both sets gives the proportion of the connective tissue compartment of the heart. 
 
6.3 Statistical analysis  
 
All values are presented as mean ± SEM. In the in vitro viability and proliferation studies 
one-way analysis of variance (ANOVA) followed by Fisher’s or least significant difference 
(LSD) post-hoc tests or Dunnet’s post-hoc tests were used to evaluate differences between 
groups. In case of superoxide and ROS determinations two experimental groups were analyzed 
with the t-test. Western blot results were analyzed with two-way analysis of variance (ANOVA). 
In the in vivo study, the statistical analysis was performed using Sigmaplot 12.0 for Windows 
(Systat Software Inc, Chicago, Illinois, USA). Baseline and different follow-up data including 
body weight and echocardiographic parameters were compared by means of repeated measures 
two-way ANOVA among the control and irradiated groups. All other parameters were compared 
by unpaired t-tests between the control and the irradiated groups. P<0.05 was accepted as 
statistically significant.  
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7 RESULTS 
 
7.1 In vitro study 
 
To determine optimal experimental conditions, NRVM were exposed to various radiation 
doses, and viability was measured following varying latency times (Table I). A significant cell 
loss of 50% was obtained after 10 Gy dose of radiation and latency time of 48 hours. This set of 
conditions was chosen and applied throughout all the experiments. 
 
Time after irrad.   5 Gy 10 Gy 15 Gy 20 Gy 
 
0 h  100 ±2 98 ±2 95 ±2 96 ±3 
24 h  76 ±2 75 ±3 79 ±4 89 ±6 
48 h  63 ±2 50 ±2 43 ±1 44 ±1 
72 h  58 ±3 49 ±3 43 ±3 42 ±2 
96 h  71 ±7 78 ±8 53 ±3 49 ±3 
120 h  50 ±2 38 ±1 37 ±1 39 ±2 
 
Table 1 Cell survival in function of irradiated NRVM. Cell survival in ratio to control (%). 
 
First, the effect of hGHRH was tested on cell viability and cell proliferation in unirradiated 
and irradiated NRVM cultures. hGHRH did not significantly influence cell survival as compared 
to control (Figure 4A and B). hGHRH was tested for its effect on cell proliferation via the BrdU 
incorporation assay. Cell proliferation of both irradiated and non-irradiated cells was slightly 
stimulated by hGHRH at a concentration of 50 nM (Figure 4C). 
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Figure 4 Viability of unirradiated (A) and irradiated (B) NRVM after hGHRH treatment (48h). 
The effects of hGHRH on the proliferation of unirradiated and irradiated NRVM are shown in 
panels C and D, respectively. Data are expressed as mean ± SEM in comparison to control 
(100%); n=8-16 in each group.  
 
The effects of the GHRH agonists, JI-34 and MR-356, were first tested in unirradiated 
NRVM. The administration of JI-34 had no effect on cell viability at concentrations of 1-500 nM 
(Figure 5A). However, in irradiated cells, JI-34 showed a protective effect at concentrations of 10 
and 100 nM (Figure 5B). Anti-proliferative effect of JI-34 was detected at 50 nM in unirradiated 
and at 1-50 nM in irradiated cultures (Fig 5C and D). 
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Figure 5 Viability of unirradiated (A) and irradiated (B) NRVM after JI-34 treatment (48h). 
Bromodeoxyuridine (BrdU) proliferation assay performed in unirradiated (C) and irradiated 
NRVM (D), 48 h after the treatment with JI-34. Data are expressed as mean ± SEM; in 
comparison to unirradiated untreated control (100%). * p<0.05, n=8-16 in each group. 
 
We have tested the same parameters under serum-deprived conditions to test the possible 
effects of the absence of 1% FBS including the avoidance of the binding of the analogs to the 
plasma proteins. NRVM cultures maintained in serum-free medium for 2 days contained roughly 
50% less cells both in the irradiated and unirradiated plates (Figure 6A). Again, a strong 
protective effect of JI-34 was detected after irradiation, at concentrations of 10 and 100 nM 
(Figure 6B).  
 
 
Figure 6 NRVM cell viability cultured with or without 1% FBS. Unirradiated and irradiated 
cultures were compared after 48 h of latency time (A). Viability of irradiated NRVM cells after 
JI-34 treatment, cultured without FBS supplementation; data are expressed as mean ± SEM; in 
comparison to control (100%). * p<0.05, n=8-16 in each group (B). 
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The GHRH agonist, MR-356, had no significant effect on cell survival in unirradiated 
NRVM cultures (Figure 7A), but prevented cell loss at a concentration of 500 nM after 
irradiation (Figure 7B). No proliferative effect of MR-356 was detected in either the unirradiated 
or the irradiated cultures (Figure 7C and D). 
        
 
Figure 7 Viability of unirradiated (A) and irradiated (B) NRVM after MR-356 treatment. 
Bromodeoxyuridine (BrdU) proliferation assay performed in unirradiated (C) and irradiated 
NRVM (D) 48 h after the treatment with MR-356. Data are expressed as mean ± SEM; in 
comparison to control (100%). * p<0.05, n=8-16 in each group. 
 
In order to investigate the expression of GHRHRs in NRVM at the protein level, Western 
blot analysis was performed using an antibody able to detect pGHRHRs. A 52 kDa protein 
isoform was readily detected in the samples together with GAPDH used as internal control 
(Figure 8A). This 52 kDa glycosylated GHRHR was expressed in both irradiated and unirradiated 
cells. The treatment of cells with JI-34, did not influence the expression of GHRHRs (probably 
due to optimal dose of agonist) in irradiated (Figure 8B) or unirradiated NRVM (Figure 8C). 
Irradiation caused significant decline in receptor expression after 48 hours. 
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Figure 8 Western blot analysis: pGHRHR and GAPDH housekeeping gene expression (A). The 
expression of GHRHR was normalized to the GAPDH housekeeping gene in unirradiated (B) and 
irradiated (C) NRVM cultures. Western blots were performed both on untreated cells and cells 
treated with 10 nM JI-34. Results are mean ± SEM (expressed in % as compared to non-treated 
cells); n=6 sample/group, *p<0.05. 
 
For further investigation of intracellular action of GHRH agonists, the activation of 
RISK/SAFE pro-survival kinases was tested. The phosphorylation ratio of ERK significantly 
increased after the irradiation with 10 Gy, which was significantly attenuated by JI-34 treatment 
(Figure 9).  
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Figure 9 The expression of pERK/ERK and the expression of GAPDH housekeeping gene in 
unirradiated and irradiated NRVM cultures. Western blots were performed both on untreated 
cells and cells treated with 10 nM JI-34. Results are mean ± SEM; *p<0.05 as compared to 
unirradiated, #p<0.05 as compared to unirradiated, after JI-34 treatment. Panel B and C show two 
independent experiments. 
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Likewise, the phosphorylation ratio of AKT significantly increased after the 10 Gy 
irradiation which was significantly attenuated after JI-34 treatment (Figure 10). 
 
Figure 10 The expression of pAkt/Akt and the expression of GAPDH housekeeping gene in 
unirradiated and 10 Gy irradiated NRVM cultures. Western blots were performed both on 
untreated cells and cells treated with 10 nM JI-34. Results are mean ± SEM; *p<0.05 as 
compared to unirradiated values with the irradiated values, #p<0.05 as compared to initial 
unirradiated values with the JI-34 treated values. *p<0.05 as compared to unirradiated, #p<0.05 
as compared to unirradiated, after JI-34 treatment. Panel B and C show two independent 
experiments. 
 
Next, JI-34 agonist was additionally tested for its possible effect on ROS production. Both 
the overall level of ROS and that of superoxide significantly increased 48 h after the irradiation. 
JI-34 treatment significantly decreased overall ROS production after irradiation, while MR-356 
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decreased its level in both irradiated and unirradiated cultures. Both agonists decreased 
superoxide level significantly in irradiated cultures (Figure 11). 
 
 
Figure 11 ROS production in ratio of viability (A) detected 48 h postirradiation. The effect of JI-
34 on ROS formation in unirradiated (B) and irradiated NRVM (C); the effect of MR-356 on 
ROS production in unirradiated (D) and irradiated cells (E). The superoxide level in ratio of 
viability detected 48 h after irradiation (F). The effect of JI-34 on superoxide levels in 
unirradiated (G) and irradiated NRVM (H); the effect of MR-356 on superoxide level in 
unirradiated (J) and irradiated NRVM (I). Results are mean ± SEM; *p<0.05. 
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7.2 In vivo study 
 
In the first preliminary experiment, heart irradiation with doses of 20-40 Gy caused no 
symptoms or echocardiography changes during the 14 weeks of observation; also, no animal loss 
occurred despite the apparent growth retardation due to irradiation. The radiation dose of 50 Gy, 
in the next experiment, caused tachypnea, abdominal breathing and heart functional changes with 
arrhytmias, but only after the observation time of 14 weeks. GDF-15 elevation occurred at weeks 
3, 12 and 26, TGF-beta concentrations were continuously elevating during the observation period 
until the maximum value at week 12 (Figure 12). Four animals were lost during anesthesia for 
echocardiography, 1 at week 18 and 3 at week 22. Hence, a radiation dose of 50 Gy and a follow-
up time of a minimum of 24 weeks were chosen for the final experiment.   
 
Figure 12 Plasma GDF-15 levels in 2 consecutive experiments (A and C) and plasma TGF-beta 
levels (B) in unirradiated controls vs. animals after selective heart irradiation. The measured data 
were analyzed by two way ANOVA and Holms-Sidak post hoc tests comparing data in the 
irradiated group with the control group (mean ± SEM, *p<0.05, **p<0.01), n=5/group. 
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Although body weight constantly increased throughout the observation period, the irradiated 
animals showed significantly lower weight gain as compared to the control animals (Figure 13). 
After week 12, irradiated animals developed tachypnea and abdominal breathing and, after week 
16, 2 animals in the irradiated group died. Due to the poor performance status of the irradiated 
animals, the experiment was terminated at week 19. 
 
 
Figure 13 Body weight in unirradiated and irradiated animals. The measure data were analyzed 
by unpaired t-test comparing data in the irradiated group with the control group (mean ± SEM, 
p<0.05 at all time points), n=10-12/group. 
 
In the third experiment, transthoracic echocardiography was performed at weeks 0, 12 and 19. 
Left ventricular systolic and diastolic anterior wall thickness in the irradiated rats was increased 
at weeks 12 and 19 as compared to both the baseline values and that in the control animals 
(Figures 14A and 15).  
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Figure 14 Left ventricular morphology as assessed by echocardiography. The parameters were 
analyzed by two way ANOVA and Holms-Sidak post hoc tests comparing data in the irradiated 
group with the control group (mean ± SEM, *p<0.05 as compared to control group within the 
same time point, #p<0.05 as compared to initial values within the same group), n=10-12/group. 
 
Likewise, in irradiated rats, diastolic septal wall thickness was increased at week 19 as 
compared to the initial values or to the control group. While left ventricular end systolic and end 
diastolic diameters increased by time in control rats indicating normal heart growth, these 
parameters in the irradiated rats failed to increase or decreased, thus indicating retarded heart 
growth (Figure 14C). Increased anterior and septal wall thickness and decreased left ventricular 
diameters of the irradiated hearts point to the presence of left ventricular hypertrophy (Figures 
14C and 15). Echocardiography performed at week 19, in addition, indicated the presence of 
arrhythmias. 
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Figure 15 Representative M-mode echocardiographic images in cross section. Anterior wall, left 
ventricular diameters and inferior wall in systole and diastole represent 5 cardiac cycles at week 
0, 12 and 19 in a control and in an irradiated animal.  
 
Irradiated animals demonstrated increased fractional shortening as compared to controls, at 
week 19 (Figure 16A). Physiological heart rate decrease, due to aging apparent in control rats, 
was lacking in irradiated animals (Figure 16B). Isovolumic contraction time was significantly 
increased in irradiated animals at weeks 12 and 19 as compared to the baseline or to that in 
control rats at week 19 demonstrating impaired systolic function after irradiation (Figure 16C). 
Other systolic parameters, maximal flow velocity and pressure gradient through the left 
ventricular outflow tract were significantly decreased in the irradiated rats as compared to 
controls at weeks 12 and 19 (Figures 16D-E). The ratio of the early flow velocity E and the septal 
mitral annulus velocity e' was significantly increased in the irradiated rats as compared to the 
baseline values or to that of controls at week 19, indicating diastolic dysfunction (Figure 16F). 
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Figure 16 Left ventricular function as assessed by echocardiography. The parameters were 
analyzed by two way ANOVA and Holms-Sidak post hoc tests comparing data in the irradiated 
group with the control group (mean ± SEM, *p<0.05 vs. control group within the same time 
point, #p<0.05 vs. week 0 within the same group), n=10-12/group. 
 
The early peak of GDF-15, 3 weeks after the irradiation, was confirmed (Figure 12C).   
At autopsy, the most common finding was the presence of extensive pleural fluid (11.3±1.7 
ml, n=10) in irradiated animals. Neither abnormal macroscopic heart changes (including the large 
vessels, the valves, the coronary arteries etc.) nor sign of radiation pneumonitis or lung fibrosis 
were visible, confirming the selectivity of heart irradiation. In the irradiated group, the tibia 
length and the weight of various organs, including the heart, was significantly smaller than in the 
control group (1.3±0.06 vs. 1.7±0.07 g, p<0.05). 
Conventional morphological examinations of the pericardium, myocardium, vessels, 
perivascular, subendocardial, subepicardial areas and the coronary arteries, or the lungs, failed to 
reveal abnormalities in irradiated rats. 
In the preliminary experiments, picrosirius red staining of the heart sections failed to detect 
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fibrosis in animals irradiated with a dose of <40 Gy. In the 40 Gy heart irradiation group, slight 
but consistent fibrosis was visible after a follow-up of 26 weeks. In the final experiment, 50 Gy 
dose induced readily detectable collagen deposition appropriate for quantification after a follow-
up time of 19 weeks. Our computer-assisted quantitative method indicated significant fibrosis in 
all parts of the heart (Figure 17). 
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8 DISCUSSION 
 
 We aimed at developing reliable in vitro and in vivo (animal) models for the study of the 
effects of ionizing radiation on the heart and for testing potential radiation protective materials. 
Radiation-induced diffuse myocardium injury is time-dependent, developing after even a low 
radiation dose [5]. RIHD first starts with structural changes of the endothelial cells and myocytes 
inducing cardiac hypertrophy [5]. Later, interstitial inflammation and progressive fibrosis take 
place ultimately resulting in heart failure [44, 45]. Although much has been learned about the 
mechanisms of RIHD, the exact pathomechanisms have not been fully elucidated; furthermore, 
the identification of its early markers and the development of specific therapy for its prevention 
are needed [2, 46]. The availability of tools to prevent or to alleviate the serious side effects of 
irradiation would be indispensable for safe radiotherapy.  
8.1 In vitro study 
 
This is the first demonstration that the agonistic analogs of GHRH, JI-34 and MR-356 of 
GHRH decrease the harmful effects of irradiation on NRVM cultures both under serum-
supplemented and serum-free conditions. Apoptosis of cardiac myocytes is a common response 
to various stresses such as ischemia, nutrient deprivation, chronic catecholamine stimulation or 
radiation [30, 31, 47]. Radiation induces the apoptosis of cells by production of ROS, which 
results in DNA double strand breaks [48]. It has been shown that GHRH treatment prevents 
apoptosis induced by serum starvation or isoproterenol treatment in cardiac myocytes [30]. We 
have tested the effects of GHRH and its agonistic analogs, JI-34 and MR-356 in irradiated 
NRVM. JI-34 and MR-356, administered few hours after irradiation, increased cell viability. 
The mechanism of cardiocytoprotection of GHRH agonists is not completely clarified, and 
probably depends on the system examined. The anti-apoptotic effects of GHRH agonists have 
been demonstrated in in vivo experimental infarcts in the rat. The chronic administration of the 
GHRH-agonist JI-38 upregulated the expression of the anti-apoptotic BCL2, while down-
regulated that of the proapoptotic BAX gene, and increased the proliferation of cardiac precursor 
cells in experimental heart infarcts [35]. In a similar system, GHRH agonists reduced the 
expression of inflammatory and pro-fibrotic markers [31]. In H9c2 cardiomyoblasts cultured 
under serum-deprived condition, agonistic analogs of GHRH repressed the expression of a series 
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of genes related to cardiac remodeling [31]. Some studies conclude to that GHRH or its agonistic 
analogs modulate the kinases included in the RISK and SAFE pathways [30, 32]. GHRH 
treatment prevented apoptosis induced by serum starvation or isoproterenol treatment in cardiac 
myocytes through the interaction with multiple signaling mechanisms involving the 
cAMP/protein kinase A, ERK 1/2 and PI3K/Akt pathways [30]. GHRH protected the rat heart 
from I/R-caused injury administered at reperfusion via activation of the RISK and SAFE 
pathways, as measured 20 min after the start of reperfusion [32]. The early activation of ERK 1/2 
and Akt was detected by Granata, in serum-deprived isolated cardiac myocytes [30]. In our study, 
the post-irradiation administration of GHRH agonists also strongly affected the activation of the 
SAFE/RISK signaling pathways. Both JI-34 and MR-356 treatment significantly decreased 
phosphorylation of Akt and ERK after 48h of latency time. Their protective effect may be 
explained by this phenomenon since irradiation induces the MAPK pathway and the 
phosphorylation of ERK via ROS formation [49]. In fact, our study indicates that the agonistic 
analogs of GHRH directly influence oxidative stress. ROS formation readily detectable 48 h after 
the irradiation was effectively reduced by the post-irradiation administration of JI-34 and MR-
356. The pretreatment of C3H mice with the GHRH antagonist, JMR-132, caused a response 
dependent on the radiation dose of whole body radiation [47, 50]. 
The effects of GHRH or the agonistic analogs are mediated by the GHRHR. The 
administration of GHRH antagonists together with GHRH or its agonistic analogs abolished its 
protective effects on cardiomyocytes [30, 32]. We believe that GHRH and its receptors have 
physiological roles in the recovery from cell injury, and that the explanation for our findings in 
NRVM is the presence and function of the GHRHR. Granata et al. have demonstrated both the 
mRNA and protein expression of the pGHRHR in cardiac cells [30]. The pGHRHR has been 
detected in rat hearts by means of Western blotting, immunohistochemistry and ligand binding 
assay [35]. In consistence with these findings, we showed the presence of a 52 kDa protein 
isoform of GHRHR with Western blotting; the expression of this protein declined by time in 
irradiated NRVM, irrespective of whether JI-34 treatment was applied. The difference the 
irradiation made may point to the role of the GHRH system in cell recovery after radiation injury.  
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8.2 In vivo study 
 
 For the study of RIHD, an animal model for the selective irradiation of the heart and 
prevention of radiation-induced pneumonitis is essential. In our in vivo model using adult male 
Sprague-Dawley rats, we developed a selective heart irradiation technique, and studied the effects 
of both the dose and time of follow-up. We have studied the kinetics of inflammatory mediators, 
the heart function (ECG and transthoracic echocardiography), morphological changes, and 
intended to test new potential therapeutic agents that could influence radiogenic heart injury [51, 
52].  
 The use of 50 Gy dose for heart irradiation provided drastic functional and morphological 
changes, some of them already present at 12 weeks. The time course of radiogenic, 
morphological and functional changes was similar to that in other studies [5, 3, 15]. Interstitial 
collagen deposition is thought to be progressive [5, 53, 54]; our experiments indicate that no 
abnormality occurs earlier than 5-6 months post-irradiation, even if a large dose is applied. 
Lately, we observed chronic cardiovascular and ventilatory insufficiency, partly due to 
pulmonary toxicity related to heart irradiation [55]. It is thought that the pathomechanism of 
RIHD in humans consists of progressive atherosclerosis of the coronary arteries due to 
endothelial damage, as well as diffuse injury of the myocardium [1, 2]. The injury to the 
macrovasculature is difficult to test due to the absence of risk factors for coronary artery disease 
in experimental animals. We fed the animals with lipid-rich chow, but, despite the large radiation 
dose, no signs of macrovasculature changes were seen. For the detection of the loss of capillaries, 
no special staining was used. Conventional morphological methods, including hematoxylin and 
eosin or the Crossman trichrome stain of connective tissue, failed to reveal differences between 
unirradiated and irradiated animals’ hearts even after the use of a dose of 40 Gy. Using the 
picrosirius red/fast green staining method, after the delivery of 40 Gy and a follow-up time of 22-
26 weeks, there was slightly more apparent interstitial fibrosis in irradiated hearts. Since 
interstitial fibrosis is a major final end-point of radiogenic damage of all risk organs, a computer-
assisted quantitative method adequate for future radiobiology investigations was developed to 
measure this parameter.  
Pleural fluid is a well-known consequence of heart irradiation due to - and explained by - 
radiation pericarditis: the pericardium in rodents is interconnected with the pleural space and the 
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origin of pleural fluid is thought to be pericardial fluid [5]. Pleural fluid, related to high-dose 
irradiation, was absent below the dose of 20 Gy both in our hands and the literature [15, 56]. In 
our experiments, no histological abnormalities related to pericardial damage were seen, despite 
the fact that the pericardium was exposed to irradiation. We intended to find early markers that 
could predict consequent damage after heart irradiation. GDF-15 is related to a series of heart 
abnormalities [56-62]. We think that GDF- 15 elevation 3 weeks after the irradiation reflected an 
early stress-response, while its increase at weeks 12 and 26 was rather a consequence of heart 
failure. Fibrosis is a self-stimulating vicious circle resulting in the progressive nature of the 
process. The blockade of the key mediator TGF-beta may prevent or mitigate fibrosis [63]. In the 
present model, increased values of TGF-beta at week 12, predicted fibrosis in yet asymptomatic 
animals. In future experiments, GDF-15 and TGF-beta determination could serve as early 
parameters for testing radioprotective agents. 
8.3 New findings 
 
The agonistic analogs of GHRH, JI-34 and MR-356 reduce radiation-induced cell loss in in vitro 
cultured NRVM, the mechanisms of action include the attenuation of the phosphorylation ratio of 
ERK and AKT and the reduction of radiation-induced superoxide production. Based on these 
preliminary findings, the agonistic analogs of GHRH should be tested in vivo as potential 
protective agents against radiogenic heart damage. 
An animal model for the comprehensive study of radiation heart damage has been developed. The 
identification of biochemical, functional and morphological parameters may serve as predictive 
markers or study endpoints in future experiments. Samples collected during the experiments 
provide instant possibility to further investigate the pathomechanisms of radiation damage. The 
model may be used for testing potential protective agents for the prevention of heart sequelae.   
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9 CONCLUSIONS 
 
Our in vitro experiments suggest a role for GHRH and its receptors in response to irradiation in 
cardiomyocytes. The agonistic analogs of GHRH, JI-34 and MR-356 exert protective effects in 
irradiated NRVM cultures; hence the study of GHRH analogs in in vivo experiments seems to be 
justified. Our NRVM radiobiology model provides appropriate system for testing other 
cardioprotective agents, too. 
The reported selective heart irradiation in vivo rat model provides various readily measurable 
end-points for future radiobiology experiments. The short-term (circulatory inflammatory 
cytokines) and medium-term (heart functional abnormalities) objectives may be used to test 
protective agents in the same setting, while if comprehensive or long-term measures (fibrosis and 
other morphology endpoints) are needed, both the radiation dose should be lowered and the 
follow-up time might be extended. Ultimately, this radiobiology model should be used for testing 
cardioprotective agents including the agonistic analogs of GHRH.   
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